Government-Owned Inventions; Availability for Licensing, 77885-77887 [2010-31319]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices
Genetics and Visual Function Branch, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
use of nitisinone (NTBC) for
oculocutaneous albinism or as a
treatment for increasing pigmentation in
the eyes, hair and/or skin of patients.
Please contact Alan Hubbs, PhD at 301–
594–4263 or hubbsa@mail.nih.gov for
more information.
srobinson on DSKHWCL6B1PROD with NOTICES
Modulators of Survival Motor Neuron
Production
Description of Invention: This
technology discloses compounds that
modulate the amount of Survival Motor
Neuron protein (SMN). Low levels of
SMN protein are associated with Spinal
Muscular Atrophy (SMA), which
constitutes a group of inherited diseases
that cause progressive muscle
degeneration leading to death.
Consequently, therapeutic inventions
have focused on increasing SMN protein
levels. This invention discloses novel
arylthiazolyl piperidines which are
shown to be modulators of SMN
production. This invention also
discloses methods of treating SMA by
administering SMN protein modulators.
Applications: Therapeutic
developments for Spinal Muscular
Atrophy.
Advantages: Small molecule (series of
analogs can be derived in search of
improved performance).
Development Status:
• Pre-clinical; no animal data.
• In vitro data available.
Market: Muscular dystrophy.
Inventors: Juan Jose Marugan
(NHGRI–NCGC); Wei Zheng (NHGRI–
NCGC); Noel Southall (NHGRI–NCGC);
Jingbo Xiao (NHGRI–NCGC); Steve Titus
(NHGRI–NCGC); Elliot Androphy
(University of Massachusetts Medical
School); Jonathan Cherry (University of
Massachusetts Medical School).
Patent Status: U.S. Provisional
Application No. 61/323,963 filed 14
April 2010 (HHS Reference No. E–109–
2010/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Steven H.
Standley, PhD; 301–435–4074;
sstand@mail.nih.gov.
Collaborative Research Opportunity:
The NIH Chemical Genomics Center
(NCGC), National Human Genome
Research Institute, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize these SMN modulator
compounds. Please contact Dr. Juan
VerDate Mar<15>2010
17:09 Dec 13, 2010
Jkt 223001
Marugan at maruganj@mail.nih.gov for
more information.
Use of Sterculic Acid To Treat
Choroidal Neovascularization
Description of Invention: Sterculic
acid is a naturally occurring
cyclopropene acid present in kapok
seed oil, cottonseed oil, and in the seeds
of the Sterculia foetida tree. Sterculic
acid has been reported to be a nonspecific inhibitor of stearoyl-Co
desaturase (SCD), which has been
implicated in several disease states,
including cardiovascular disease,
obesity, non-insulin-dependent diabetes
mellitus, skin disease, hypertension,
neurological diseases, immune
disorders and cancer (Ntambi JM, J.
Lipid Res., 1999, 40(9):1549–1558). NIH
investigators have recently discovered
that sterculic acid inhibits the
neovascularization of the chick
chorioallantonic membrane
demonstrating that this compound
exhibits a potent anti-angiogenic
activity. Further, the NIH investigators
have shown that sterculic acid inhibits
the formation of choroidal
neovascularization in the retina of laser
treated rats. These results suggest that
sterculic acid possesses anti-angiogenic
effect likely through regulating genes
involved in the angiogenic process.
The present invention is directed to
methods of using sterculic acid for the
treatment of inflammation, in particular,
7-ketocholesterol mediated
inflammation, 7-ketocholesterol
cytotoxicity, or unregulated
angiogenesis. Diseases mediated by 7ketocholesterol-induced inflammation
and 7-ketocholesterol cytotoxicity
include atherosclerosis age-related
macular degeneration, and Alzheimer’s
disease. Diseases mediated by
unregulated angiogenesis include
certain cancers and age-related macular
degeneration. Also disclosed are
methods of treating atherosclerosis or
Alzheimer’s disease using sterculic acid.
Applications: Therapeutics for
inflammation, in particular,
atherosclerosis, age-related macular
degeneration, and Alzheimer’s disease
Development Status: Early stage in
vitro and animal model data.
Inventors: Ignacio R. Rodriguez et al.
(NEI).
Patent Status: U.S. Provisional
Application No. 61/358,485 filed 25 Jun
2010 (HHS Reference No. E–092–2010/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Suryanarayana
Vepa, PhD, J.D.; 301–435–5020;
vepas@mail.nih.gov.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
77885
Collaborative Research Opportunity:
The National Eye Institute (NEI),
Laboratory of Retinal Cell and
Molecular Biology, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize sterculic acid, and its
derivatives for the treatment of diseases
related to angiogenesis or mediated by
7-ketocholesterol-induced
inflammation. Please contact David L.
Whitmer, Technology Development
Coordinator, NEI, at 301–496–4876 or
whitmerd@mail.nih.gov for more
information.
Dated: December 8, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–31320 Filed 12–13–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Software System for Quantitative
Assessment of Vasculature in Three
Dimensional Images
Description of Invention:
This invention offered for licensing
and further development is a software
system that provides the capability of
E:\FR\FM\14DEN1.SGM
14DEN1
srobinson on DSKHWCL6B1PROD with NOTICES
77886
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices
efficiently extracting, visualizing and
quantifying three dimensional vascular
networks from medical and basic
research images. Deregulation of
angiogenesis plays a major role in a
number of human diseases, most
notably cancer. A substantial increase in
the research effort in this field over the
past decade has deepened the
understanding of the angiogenic
process. However, the lack of methods
and software to quantitatively assess
vasculature in patients has considerably
hampered the ability to directly study
the angiogenesis process, as well as to
discover and develop new therapeutics
to modulate angiogenesis. The present
invention provides new semi-automated
computer algorithms, statistical
methods and user friendly visualization
tools for rapid and intuitive quantitative
evaluation of vasculature in three
dimensional data sets obtained through
non-invasive imaging techniques such
as MRI, CT–Scans, confocal microscopy,
microCT, etc. The methods and software
embodied in this invention provide a
three dimensional quantitative
capability in the clinic as a vascular
diagnostic tool and in basic research
projects to evaluate changes in vascular
network systems.
Applications:
• Medical research for studying
angiogenesis and tumor vasculature.
• Potential applications in clinical
studies and diagnostics.
• Discovery and development of antiangiogenesis agents with application to
cancer.
• Possible application to diseases
other than cancer, such as those related
to the lymphatic system, the pulmonary
airway, the kidney filtration system.
Development Status:
• The invention is fully developed.
• The software will be readily
available if so requested.
Inventors: Enrique Zudaire,
Christopher Kurcz, Yanling Liu (NCI).
Patent Status: HHS Reference No. E–
261–2010/0—Software. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
licensing.
Licensing Contacts:
• Uri Reichman, PhD, MBA; 301–
435–4616; UR7a@nih.gov.
• Michael Shmilovich, Esq.; 301–
435–5019; ShmilovichM@mail.nih.gov.
Compounds That Treat Malaria and
Prevent Malaria Transmission
Technology Summary: The invention
offered for licensing relates to
therapeutic compounds and related
pharmaceutical compositions that can
be used in the prevention and treatment
VerDate Mar<15>2010
17:09 Dec 13, 2010
Jkt 223001
of malaria infection. More specifically,
the invention is drawn to compounds
that can kill malaria gametocytes to
block malaria transmission and treat
malaria infection in the non-erthtrocytic
stages, as well as therapeutic uses of
these molecules to prevent or slow the
transmission of plasmodium organisms
between mammals and eliminate or
prevent infection in mammal.
Furthermore, the compounds of the
invention are tricyclic compounds
where the side rings may be 5–7
membered rings (preferably 6membered), and the center ring may be
6–8 membered ring (preferably 7membered). Also preferable structures
are ones in which the side rings are aryl
rings while the center ring is cycloalkyl
ring. The compounds of the invention
have been identified by integrating
quantitative high-throughput screening
(qHTS) with genetic mapping and in
vivo oocyst formation assay.
Applications: Prevention and
treatment of malaria infections.
Inventors: Xin-zhuan Su and Jing
Yuan (NIAID).
Patent Status: International Patent
Application No. PCT/US2010/047019
filed August 27, 2010. Priority
Application 61/237,417 filed August 27,
2009. (HHS Reference No. E–283–2009).
Licensing Status: Available for
licensing.
Licensing Contacts:
• Uri Reichman, PhD, MBA; 301–
435–4616; UR7a@nih.gov.
• Michael Shmilovich, Esq.; 301–
435–5019; ShmilovichM@mail.nih.gov.
A Universal Antigen Delivery Platform
for Enhanced Immune Response
Description of Invention: The present
invention relates to use of the rotavirus
NSP2 octamer as a universal antigen
delivery platform for presenting a high
density of neutralizing epitopes to the
immune system, a strategy for boosting
antigen immunogenicity. This
application is advanced by the welldefined structural and biochemical
properties of the octamer, its high
stability at a broad range of pH,
temperature and ionic stability, and its
ease of purification (one step) under
nondenaturing conditions. Long
conformationally-dependent antigens
are readily mounted onto the platform
by fusion to the C-terminus of NSP2, a
region of the NSP2 protein positioned
on the exposed surface of the octamer.
The platform can be expressed in and
purified from prokaryotic and
eukaryotic systems.
This technology can be used for rapid
production of subunit vaccines against a
wide range of infectious agents.
Additional uses of the technology
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
include the generation of delivery
platforms with mounted short peptide
antigens for use in cancer
immunotherapy, production of specific
antisera to conformationally and
nonconformationally-dependent
antigens for research purposes, and
development of epitope targets and
short peptide-antigen presentation
platforms for diagnostic assays.
Applications:
• Vaccines against pathogens.
• Cancer vaccines.
• Antigen-specific antisera.
• Multivalent targets in diagnostic
assays.
Advantages:
• Octameric platform is stable,
efficiently expressed, and easily
purified by a single step method.
• Enables the display of multivalent
conformation-dependent epitopes.
• Effective platform for short peptides
as well as long polypeptides.
Development Status: Proof-of-concept
experiments have shown that the
octamer mounted with short peptides or
long multivalent polypeptides retains its
structural and biophysical features and
is highly effective in presenting foreign
antigens to the immune system. Ease of
purification and final protein yields of
the short or long peptide antigenmounted NSP2 octamers were
comparable suggesting that the platform
accommodates a large range of antigen
sizes. The NSP2-platform also served as
an adjuvant, significantly enhancing
immunity of the mounted peptide.
Inventors: John T. Patton (NIAID);
Zenobia F. Taraporewala (NIAID).
Relevant Publications:
1. P Schuck et al. Rotavirus
nonstructural protein NSP2 selfassembles into octamers that undergo
ligand-induced conformational changes.
J Biol Chem. 2001 Mar 30;276(13):9679–
9687. [PubMed: 11121414]
2. H Jayaram et al. Rotavirus protein
involved in genome replication and
packaging exhibits a HIT-like fold.
Nature. 2002 May 16;417(6886):311–
315. [PubMed: 12015608]
3. Z Taraporewala et al. Rotavirus
NSP2 octamer as an epitope-mounting
platform. Abstract, 23rd Annual
Meeting of the American Society for
Virology, 2004.
4. K Kearney et al. Cell-line-induced
mutation of the rotavirus genome alters
expression of an IRF3-interacting
protein. EMBO J. 2004 Oct
13;23(20):4072–4081. [PubMed:
15372078]
Patent Status: U.S. Patent Application
No. 11/293,654 filed 02 Dec 2005 (HHS
Reference No. E–322–2004/0–US–02).
Licensing Status: Available for
licensing.
E:\FR\FM\14DEN1.SGM
14DEN1
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices
Licensing Contact: Kevin W. Chang,
PhD; 301–435–5018;
changke@mail.nih.gov.
Dated: December 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–31319 Filed 12–13–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
srobinson on DSKHWCL6B1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Sardinia.
Date: January 19, 2011.
Time: 3 p.m. to 6 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call)
Contact Person: Jeannette L. Johnson, PhD,
Scientific Review Officer, National Institutes
on Aging, National Institutes of Health, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7705,
JOHNSONJ9@NIA.NIH.GOV.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Development
and Maintenance of an Aged Rodent Tissue
Bank.
Date: January 27, 2011.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call)
Contact Person: Bita Nakhai, PhD,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, Gateway
Bldg., 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20814, 301–402–7701,
nakhaib@nia.nih.gov.
VerDate Mar<15>2010
17:09 Dec 13, 2010
Jkt 223001
Name of Committee: National Institute on
Aging Special Emphasis Panel; Development
and Maintenance of a Multigenotypic Aged
Rat Colony.
Date: January 27, 2011.
Time: 12 p.m. to 1:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call)
Contact Person: Bita Nakhai, PhD,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, Gateway
Bldg., 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20814, 301–402–7701,
nakhaib@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 8, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–31322 Filed 12–13–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council on Aging.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Aging.
Date: January 25–26, 2011.
Closed: January 25, 2011, 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
77887
Place: National Institutes of Health,
Building 31, 31 Center Drive, C Wing,
Conference Room 6, Bethesda, MD 20892.
Open: January 26, 2011, 8 a.m. to 12:45
p.m.
Agenda: Call to order and reports from the
Director; discussion of future meeting dates;
consideration of minutes from last meeting;
reports from the Task Force on Minority
Aging Research, the Working Group on
Program, and Council of Councils; council
speaker Dr. Eileen Crimmins; and Program
Highlights.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C Wing,
Conference Room 6, Bethesda, MD 20892.
Closed: January 26, 2011, 12:45 p.m. to
1:15 p.m.
Agenda: To review and evaluate the
Intramural Research Program.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C Wing,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Robin Barr, PhD, Director,
National Institute on Aging, Office of
Extramural Activities, Gateway Building,
7201 Wisconsin Avenue, Bethesda, MD
20814, (301) 496–9322, barrr@nia.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nih.gov/nia/naca/, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 8, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–31321 Filed 12–13–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 75, Number 239 (Tuesday, December 14, 2010)]
[Notices]
[Pages 77885-77887]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-31319]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Software System for Quantitative Assessment of Vasculature in Three
Dimensional Images
Description of Invention:
This invention offered for licensing and further development is a
software system that provides the capability of
[[Page 77886]]
efficiently extracting, visualizing and quantifying three dimensional
vascular networks from medical and basic research images. Deregulation
of angiogenesis plays a major role in a number of human diseases, most
notably cancer. A substantial increase in the research effort in this
field over the past decade has deepened the understanding of the
angiogenic process. However, the lack of methods and software to
quantitatively assess vasculature in patients has considerably hampered
the ability to directly study the angiogenesis process, as well as to
discover and develop new therapeutics to modulate angiogenesis. The
present invention provides new semi-automated computer algorithms,
statistical methods and user friendly visualization tools for rapid and
intuitive quantitative evaluation of vasculature in three dimensional
data sets obtained through non-invasive imaging techniques such as MRI,
CT-Scans, confocal microscopy, microCT, etc. The methods and software
embodied in this invention provide a three dimensional quantitative
capability in the clinic as a vascular diagnostic tool and in basic
research projects to evaluate changes in vascular network systems.
Applications:
Medical research for studying angiogenesis and tumor
vasculature.
Potential applications in clinical studies and
diagnostics.
Discovery and development of anti-angiogenesis agents with
application to cancer.
Possible application to diseases other than cancer, such
as those related to the lymphatic system, the pulmonary airway, the
kidney filtration system.
Development Status:
The invention is fully developed.
The software will be readily available if so requested.
Inventors: Enrique Zudaire, Christopher Kurcz, Yanling Liu (NCI).
Patent Status: HHS Reference No. E-261-2010/0--Software. Patent
protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Licensing Contacts:
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
Michael Shmilovich, Esq.; 301-435-5019;
ShmilovichM@mail.nih.gov.
Compounds That Treat Malaria and Prevent Malaria Transmission
Technology Summary: The invention offered for licensing relates to
therapeutic compounds and related pharmaceutical compositions that can
be used in the prevention and treatment of malaria infection. More
specifically, the invention is drawn to compounds that can kill malaria
gametocytes to block malaria transmission and treat malaria infection
in the non-erthtrocytic stages, as well as therapeutic uses of these
molecules to prevent or slow the transmission of plasmodium organisms
between mammals and eliminate or prevent infection in mammal.
Furthermore, the compounds of the invention are tricyclic compounds
where the side rings may be 5-7 membered rings (preferably 6-membered),
and the center ring may be 6-8 membered ring (preferably 7-membered).
Also preferable structures are ones in which the side rings are aryl
rings while the center ring is cycloalkyl ring. The compounds of the
invention have been identified by integrating quantitative high-
throughput screening (qHTS) with genetic mapping and in vivo oocyst
formation assay.
Applications: Prevention and treatment of malaria infections.
Inventors: Xin-zhuan Su and Jing Yuan (NIAID).
Patent Status: International Patent Application No. PCT/US2010/
047019 filed August 27, 2010. Priority Application 61/237,417 filed
August 27, 2009. (HHS Reference No. E-283-2009).
Licensing Status: Available for licensing.
Licensing Contacts:
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
Michael Shmilovich, Esq.; 301-435-5019;
ShmilovichM@mail.nih.gov.
A Universal Antigen Delivery Platform for Enhanced Immune Response
Description of Invention: The present invention relates to use of
the rotavirus NSP2 octamer as a universal antigen delivery platform for
presenting a high density of neutralizing epitopes to the immune
system, a strategy for boosting antigen immunogenicity. This
application is advanced by the well-defined structural and biochemical
properties of the octamer, its high stability at a broad range of pH,
temperature and ionic stability, and its ease of purification (one
step) under nondenaturing conditions. Long conformationally-dependent
antigens are readily mounted onto the platform by fusion to the C-
terminus of NSP2, a region of the NSP2 protein positioned on the
exposed surface of the octamer. The platform can be expressed in and
purified from prokaryotic and eukaryotic systems.
This technology can be used for rapid production of subunit
vaccines against a wide range of infectious agents. Additional uses of
the technology include the generation of delivery platforms with
mounted short peptide antigens for use in cancer immunotherapy,
production of specific antisera to conformationally and
nonconformationally-dependent antigens for research purposes, and
development of epitope targets and short peptide-antigen presentation
platforms for diagnostic assays.
Applications:
Vaccines against pathogens.
Cancer vaccines.
Antigen-specific antisera.
Multivalent targets in diagnostic assays.
Advantages:
Octameric platform is stable, efficiently expressed, and
easily purified by a single step method.
Enables the display of multivalent conformation-dependent
epitopes.
Effective platform for short peptides as well as long
polypeptides.
Development Status: Proof-of-concept experiments have shown that
the octamer mounted with short peptides or long multivalent
polypeptides retains its structural and biophysical features and is
highly effective in presenting foreign antigens to the immune system.
Ease of purification and final protein yields of the short or long
peptide antigen-mounted NSP2 octamers were comparable suggesting that
the platform accommodates a large range of antigen sizes. The NSP2-
platform also served as an adjuvant, significantly enhancing immunity
of the mounted peptide.
Inventors: John T. Patton (NIAID); Zenobia F. Taraporewala (NIAID).
Relevant Publications:
1. P Schuck et al. Rotavirus nonstructural protein NSP2 self-
assembles into octamers that undergo ligand-induced conformational
changes. J Biol Chem. 2001 Mar 30;276(13):9679-9687. [PubMed: 11121414]
2. H Jayaram et al. Rotavirus protein involved in genome
replication and packaging exhibits a HIT-like fold. Nature. 2002 May
16;417(6886):311-315. [PubMed: 12015608]
3. Z Taraporewala et al. Rotavirus NSP2 octamer as an epitope-
mounting platform. Abstract, 23rd Annual Meeting of the American
Society for Virology, 2004.
4. K Kearney et al. Cell-line-induced mutation of the rotavirus
genome alters expression of an IRF3-interacting protein. EMBO J. 2004
Oct 13;23(20):4072-4081. [PubMed: 15372078]
Patent Status: U.S. Patent Application No. 11/293,654 filed 02 Dec
2005 (HHS Reference No. E-322-2004/0-US-02).
Licensing Status: Available for licensing.
[[Page 77887]]
Licensing Contact: Kevin W. Chang, PhD; 301-435-5018;
changke@mail.nih.gov.
Dated: December 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-31319 Filed 12-13-10; 8:45 am]
BILLING CODE 4140-01-P
